AIM-CD3
Automated CD3+ cell assessment for celiac disease
Software · Cloud SaaSCompany source
Company profile
About PathAI
PathAI is dedicated to improving patient outcomes with reliable AI-powered technology and meaningful collaboration with biopharma and pathology laboratories.
Company description PathAI official website
Mission. Our Mission is to Improve Patient Outcomes with AI-Powered Pathology.
Primary marketPathology & Laboratory Diagnostics
Commercial modelCommercial information available on request
Work at PathAI?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- breast cancer
- celiac disease
- colorectal cancer
- dermatopathology
- inflammatory bowel disease
- lung cancer
- MASH (metabolic dysfunction-associated steatohepatitis)
- oncology
- prostate cancer
- skin cancer
- ulcerative colitis
Who it serves
- Academic Medical Centers
- BioPharma
- Central Pathology Laboratories
- Health Systems
- Reference Laboratories
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsEuropean Union · United Kingdom · United States
Company sourceOfficial website
Company milestones
Platform expansion
PathAI entered definitive merger agreement to be acquired by Roche (2026). FDA clearance for AISight Dx Platform for primary diagnosis (June 2025). FDA Qualification for AIM-MASH AI Assist (December 2025). Expanded collaboration with Labcorp (February 2026). Partnership with MedStar Health (April 2026). Launch of AIM-HI UC and IBDExplore (February 2026).
Partnerships
Recorded partners
- Deep Bio
- DoMore Diagnostics
- Labcorp
- MedStar Health
- MindPeak
- Paige
- Primaa
- Roche (definitive merger agreement)
- Stratipath
- Visiopharm
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
AIM-HI-UC
Automated Geboes scoring for ulcerative colitis
Software · Cloud SaaSCompany source
AIM-IHC Breast Panel
AI-based measurement panel for breast cancer biomarkers
Software · Cloud SaaSCompany source
AIM-MASH AI Assist
FDA-qualified AI tool for MASH clinical trials
Software · Cloud SaaSCompany source
AIM-PD-L1
AI-powered PD-L1 biomarker detection and quantification
Software · Cloud SaaSCompany source
AIM-Tumor Cellularity
Automated tumor-cellularity assessment for molecular testing
Software · Cloud SaaSCompany source
AISight Clinical Trials
AI-enabled clinical development platform for biopharma trials
Platform · Cloud SaaSCompany source
AISight Consults
Pathology consultation services integrated with digital pathology
Service · Cloud SaaSCompany source
AISight Dx Digital Pathology Platform
FDA-cleared digital pathology platform for primary diagnosis
Platform · Cloud SaaSCompany source
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Standardized, repeatable ulcerative colitis histology scoring and endpoint assessment using an automated, foundation model-based tool.medRxiv : the preprint server for health sciences · Jul 9, 2026
Machine Learning Assessment of Pathologic Response in Lung Cancer Resections After Neoadjuvant Therapy-IASLC MPR Project.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · Jun 1, 2026
Agreement Across 10 Artificial Intelligence Models in Assessing Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Breast Cancer Whole-Slide Images.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · Feb 1, 2026
Digital Versus Manual PD-L1 Scoring in Advanced NSCLC From the IMpower110 and IMpower150 Trials.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · Dec 1, 2025
Analytical Comparison of Commonly Used Laboratory-Developed Tests for the Assessment of Ki-67 in Breast Carcinoma With a Food and Drug Administration-Approved Benchmark.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · Oct 1, 2025
Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · Aug 10, 2025
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
450+ board-certified pathologists
in proprietary pathologist contributor network
32.5M+ annotations
contributed for AI algorithm training and validation
90% of top 15 BioPharma companies
leverage PathAI technology
MedStar Health
Deploy AISight Dx Digital Pathology Platform and advanced AI applications for anatomic pathology
Labcorp
Nationwide deployment of FDA-cleared digital pathology platform
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from PathAI
Recent articles published on PathAI's official website.
PathAI Advances AISight® Dx with the v2.21 Release: Intelligent Dashboard Controls, Enhanced Data Organization, & Enterprise-Scale Configurability
Read on PathAIPathAI’s AISight® Dx IMS Platform Supports the AISight Consults Workflow for Streamlined Digital Consult Management
Read on PathAIPathAI Advances AISight® Dx with the v2.20 Release: Enhancing Viewer Usability, Workflow Efficiency, and Platform Reliability
Read on PathAIPathAI and A.C.Camargo Cancer Center announce cooperation to expand digital pathology with AI in Brazil via SUS
Read on PathAIPathAI and MedStar Health Announce Partnership to Deploy the AISight® Dx Digital Pathology Platform and Advanced AI Applications
Read on PathAI07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Pathology & Laboratory Diagnostics
Companies applying AI to digital pathology, histopathology slide analysis, laboratory diagnostics, or biomarker discovery. Includes AI-powered interpretation of lab test results, at-home diagnostic devices with AI analysis, and platforms that analyze tissue samples or biological specimens to support clinical diagnosis.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.